Larvol Delta - Acumen-Pharmaceuticals-Completes-Enrollment-in-Phase-1-Trial-of-ACU193-First-Monoclonal-Antibody-Developed-to-Selectively-Target-Toxic-A-Oligomers-in-Patients-with-Early-Alzheimers-Disease

ACU193 - Acumen Pharma

https://www.biospace.com/article/acumen-pharmaceuticals-completes-enrollment-in-phase-1-trial-of-acu193-first-monoclonal-antibody-developed-to-selectively-target-toxic-a%CE%B2-oligomers-in-patients-with-early-alzheimer-s-disease/

Feb 13, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next